(Afdhal, 2014b) This regimen was well tolerated in all groups, with
no serious adverse events reported in the 12-
week regimen with or without RBV. In the population with cirrhosis, patients treated for 24 weeks had higher SVR rates than those treated for 12 weeks, supporting the recommendation that HCV treatment–experienced patients with cirrhosis receive 24 weeks of treatment without RBV.